MLL gene fusions are the hallmark of more than 70% of therapy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause leukemia in murine transgenic models. To determine whether Mll genomic fusions can occur after exposure to topoisomerase II inhibitors, we developed a long-distance inverse PCR DNA-based assay for chimeric Mll fusions in mouse embryonic stem cells. We detected Mll fusions at a higher frequency following 100 µM etoposide for 8 h (16×10 −6 cell -1
was amplified with second-round primers: 5′-TACCCGAATCAGCAAAGCACAG-3′ (position 49611-49632) and 5′-GCTTTCTGTTCTGCCACTGTCC-3′ (48445-48424). Round 2 PCR conditions were 92°C × 2.5 min; 5 cycles at 92°C × 30 s, 59°C × 45 s, 68°C × 12 min; 10 cycles at 92°C × 30 s, 58°C × 40 s, 68°C × 12 min (+20 s/cycle), and 68°C × 8 min. PCR products were visualized by UV after size-fractionation in 1.0% agarose supplemented with ethidium bromide (0.5 mcg/ml). All samples gave the expected 10.5 kb germline Mll band. Those with alternatively sized possible Mll fusions were further analyzed by electrophoresis on a separate gel for purification (Geneclean spin kit, Q-BIOgene, Carlsbad, CA) of the nongermline bands, using minimal UV long wave irradiation. Purified PCR products were sequenced (ABIprism 3700, Applied Biosystems, Inc., Foster City, CA) with the primer: 5′-TCAGCTTCAGTTCCTGCCTC-3′ (44716-44697), by "primer walking" or by cloning with a TOPO XL kit (Invitrogen, Carlsbad, CA) for further analysis.
To verify the sensitivity of the PCR technique, a 3.3 kb plasmid containing both forward and reverse Mll primer annealing sites and a unique NcoI site was diluted in genomic DNA at a ratio of 1 copy per 60 ng of genomic DNA (corresponding to ~1 per 10,000 cells by assuming ∼6. 25 pg of DNA per cell). The mixtures were processed as above. We detected the positive control PCR signal in 12 (52%) of 23 replicates. Assuming a Poisson distribution of the plasmid DNA molecules in the PCR replicates, the expected frequency of positives was 15 (65%) of 23 replicates, which was not different than the observed frequency (p=0.56).
Frequencies of Mll fusions were estimated by assuming that every detectable fusion product represented an event and that the number of cells screened per PCR replicate was 10,000 cells. All PCR products in the 4-10.5 kb range that were readily visible on the first screening gel and on the second gel were sequenced in the etoposide-treated samples. For the control and vincristine-treated samples, fewer nongermline bands were visible, so to avoid undersampling, at least four bands were excised from each set of 24 replicates, even bands not readily visible under UV light. Comparisons of frequencies among treatment groups were made using the Chi-square test.
RESULTS
We implemented an inverse PCR strategy to detect and characterize a wide variety of lowfrequency, novel murine Mll fusion products. In humans, the vast majority of MLL gene fusions occur in an 8.3 kb BCR that encompasses exons 5 through 11 (23) . By sequence analysis, murine Mll exons 5−11 are homologous to human MLL exons 5-11. Thus, we delimited a putative murine BCR as the 11.7 kb segment flanked by two NcoI restriction sites that bracket Mll exons 5-13. Amplification of the circularized Mll BCR germline fragment yielded a single band of 10.5 kb (Fig. 1A) . The 5′ primer was positioned to maximize detection of rearrangements in intron 9, which in humans is susceptible to etoposide/topoisomerase II-induced cleavage and a DNase I hypersensitive site (24, 25) . The sizes of the Mll fusion products amplified by LDI-PCR are dictated by (a) the location of the fusion point along the Mll BCR and (b) the distance between the NcoI site on the 3′ partner and the Mll fusion point. Thus, an Mll fusion product with a relatively short non-Mll insert (e.g., 50-60 bp) fused in proximity to the annealing site of the second Mll forward primer is ~4 kb long. Amplification of Mll fusion products with non-Mll sequences of different lengths and/or fusion points located along the 6.6 kb region of interest on the Mll BCR results in discrete bands of different sizes greater than 4 kb (Fig. 1B) .
To determine whether Mll fusions can be generated after etoposide exposure, embryonic stem cells were incubated with 100 µM etoposide (8 h) Table 1 ).
The possibility that a nongenotoxic anticancer drug could also trigger the formation of Mll fusions was investigated by treating with the microtubule inhibitor vincristine. Vincristine caused the expected mitotic arrest, whereas etoposide resulted in the expected G2/M arrest when compared with no-drug controls ( Fig. 2A) . However, at comparable levels of cytotoxicity (49±5% viability after 10 µM vincristine for 48 h and 55±5% viability after 100 µM etoposide for 8 h), vincristine produced a lower level of Mll genomic fusions (1.0×10 −6 cell -1 ) than etoposide (11.0×10 −6 cell -1 P=0.0047) and was comparable to the no-drug controls (1 in 1×10   6 cells, P=1.0) (Fig. 2B ). Similar low levels of fusions were detected even after 72 h vincristine (data not shown).
We isolated 49 Mll fusion products following etoposide treatment. Each of the fusions was unique, but interestingly, they shared some common characteristics. First, 82% of the Mll partners were known or probable murine genes ( Table 2 ). The 49 partners represented 18 of the 19 murine autosomes and included a number of genes whose human orthologs have been implicated in cancer. Each chimeric product was a perfect fusion of Mll with its partner, with no deletions or insertions at the breakpoint. Of the fusions involving known or suspected genes, we confirmed that 100% of the Mll breakpoints and 94% of the partner breakpoints were localized in introns. Thirty-one percent of the Mll partners were on chromosome 9 (where Mll localizes), none of which represented intra-Mll fusions (Fig. 3) .
The breakpoints were distributed in a 1.5 kb region of Mll between exons 9 and 11 ( Fig. 3A) . Microhomologies (1-5 bp) were present at the fusion points in 74% of the products. Topoisomerase II motifs (5′-A/GNT/CNNCNNGT/CNGG/TTNT/CNT/C-3′) (26) with perfectmatch or one-mismatch sites in proximity to the fusion points (17-368 bp) were present in 44% of the chimeric products, with one Mll fusion having a topoisomerase II motif (one mismatch) located directly at the fusion point.
One of the more intriguing fusion partners was Runx1 (Fig. 4) . The Mll breakpoint was in intron 10 at position 50,547 (mCG1547), and the breakpoint in Runx1 occurred in intron 4 at position 86,948 (mCG13559), in the region homologous to the human BCR (27, 28) (23) . Using murine/human Mll exonic homology as a guide, we positioned the Mll primers to encompass up to 11.7 of a putative murine Mll BCR and detected a number of intra-and inter-chromosomal fusions. The fusions were detected using a strategy that allowed detection of "in vivo" formed Mll gene rearrangements, with Mll fusions whose breakpoints were within a putative murine BCR being susceptible to "capture" in the longdistance inverse PCR strategy employed. In addition, this allowed detection of Mll fusions while Mll and its chimeric partners were in their endogenous chromatin and cellular milieu. As the chromatin context has been hypothesized to play an important role in regulating accessibility of gene targets for rearrangement, (23, 29) particularly for MLL, there are some advantages in using endogenous DNA rather than exogenously introduced vectors for recombination assessments. Our DNA-based technique, rather than a transcript-directed method, minimized bias as to which fusion partners were detected, allowing us to more accurately quantitate the level of fusions on a per-cell basis and, generally, to survey which potential fusion partners are susceptible to fuse with Mll.
No prior descriptions of spontaneous, drug-, or irradiation-induced murine leukemias have reported translocations of Mll. Although transgenic models have demonstrated that Mll fusions are leukemogenic in mice, (6-8) such fusions have been exogenously introduced through genetic engineering, not induced by xenobiotics, as is the case in humans for topoisomerase II inhibitorassociated leukemias. Each of the fusions that we observed was unique, but interestingly, they shared some common characteristics. First, 82% of the Mll partners were known or probable murine genes (although <5% of the murine genome consists of genes) (30) . Breakpoints localizing in genes are consistent with the notion that DNA rearrangement is facilitated by gene transcription, possibly because transcription opens chromatin and facilitates accessibility of DNA to enzymes involved in cleavage and inappropriate ligation (8) . The localization of Mll and partner breakpoints in introns recapitulates that characteristic of human MLL translocations in leukemic blasts (31) , which is somewhat remarkable given the low degree of homology between human MLL and murine Mll introns (only 5 stretches of only 42-63 bp in length with 80−90% identity over introns 8−11). A lack of nucleotide deletions or insertions at the breakpoints of the fusions is consistent with sequence characteristics of some previously characterized human MLL leukemic breakpoints (12, 32) .
In humans, the most common MLL translocations are MLL/AF9 (AF9 or MLLT3 on chromosome 9), MLL/AF4 (AF4 or MLLT2 on chromosome 4), and MLL/ENL or ELL (ENL or MLLT1 and ELL, both on chromosome 19) (31, 33) . However, MLL is promiscuous, and more than 50 different partners on multiple chromosomes have been described in various human leukemias (34, 35) . Whether some genomic fusions are truly induced more commonly than others or whether differences in frequency are more related to proliferative or survival advantages conferred by some fusions more than others is not known. Among these induced murine Mll fusions, 31% of the partners were located on chromosome 9, the same chromosome where Mll localizes. Although duplications of MLL and intra-11q23 translocations have been reported in humans (36) (37) (38) , this intrachromosomal clustering of murine Mll fusions accounted for a much higher percentage than is observed in the spectrum of human MLL leukemic translocations and may reflect the different architecture of murine compared to human chromosomes (39) .
The 49 fusion partners included a number of genes whose human orthologs have been implicated in cancer. For example, Runx1 is the murine ortholog of RUNX1/AML1, a gene that has been implicated in more cases of human acute myeloid leukemia (including cases of t-ML) than any other (40) . Interestingly, to our knowledge, AML1 has never been implicated as a fusion partner of MLL and is often itself the 5′ partner in leukemic fusions. The breakpoint in Runx1 occurred in intron 4, which is analogous to human RUNX1/AML1 intron 5. Three distinctive BCRs in RUNX1/AML1 intron 5 have been identified in patients with de novo and therapy-related myeloid leukemia with AML1-ETO fusions, with some of the genomic breakpoints colocalizing with in vivo topoisomerase II and DNase I hypersensitive sites (28) . The discovery of this fusion is consistent with the notion that certain areas of the genome are predisposed to nonhomologous fusion formation, with both Mll and Runx1 displaying involvement in drug-induced fusions, as has been suggested from DNA cleavage studies in human cells (41) . Other interesting fusion partners (Table 2) included BACH2, a basic leucine zipper transcription factor, and an independent leucine zipper-containing open reading frame on chromosome 9, as this motif has been associated with known human MLL fusion partners in leukemia (e.g., AF10, AF17) (42, 43) . It seems remarkable that a relatively high percentage of drug-induced Mll fusions recapitulated the types of genes involved in leukemogenic fusions observed with drug-induced MLL fusions in patients.
Because gene fusions might be produced as a byproduct of the cytotoxic effects of any chemotherapeutic agents or proapoptotic stimulus, it is important that the fusions were induced at a much higher level with etoposide than with a similarly cytotoxic schedule of vincristine, an anticancer agent that does not inhibit topoisomerase II. It is possible that indices of Mll rearrangement (such as the genomic fusions reported herein), rather than Mll cleavage alone, may be relatively specific biomarkers for topoisomerase II inhibitor-induced leukemogenesis, rather than harbingers of apoptosis or cell death.
Microhomology of sequences was present at the breakpoints in the majority of fusions. Such short regions of homology have been demonstrated at the fusion points cloned from cases of leukemia with MLL translocations (12, 32, 44, 45) and may play some role in directing the exact position of the fusion. Although one slightly mismatched and two perfect topoisomerase II cleavage recognition sites (26) were present at or near fusion points, as has been described for human MLL translocations (24) , the utility of these sites to predict the location of topoisomerase II-mediated cleavage and their role in topoisomerase II inhibitor-associated leukemic translocations is not clear (23, 32, 44) . The larger Alu elements present near the fusion points in many MLL translocations, which have been hypothesized to help align the fusion partners in human translocations (12, 36, 46) , are not present in the murine genome (47) .
These data indicate that murine embryonic stem cells are susceptible to the same type of gene rearrangements as cause topoisomerase II inhibitor-induced leukemia in humans, including recapitulation of the target gene (the murine homologue of the MLL gene), targeting of the analogous BCR, drug-specific susceptibility, promiscuous involvement of partner genes, targeting intronic regions in both partners, and fusion with murine homologs of human leukemogenic genes. This opens the possibility of using preclinical mouse models for druginduced second cancers, as part of a strategy to avoid leukemogenesis in the future. 
